Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies,...
LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a multi-year strategic ...
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been...
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today...
LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to...
LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration...
LISCure Biosciences ("LISCure") announced that it has received approval for a global phase 1 clinical trial for two programs, LB-P6 and LB-P8,...
LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.